Recurrent Hodgkin Lymphoma Clinical Trials

38 clinical trials for Recurrent Hodgkin Lymphoma across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Personalized NK Cell Therapy in CBT — RECRUITING · PHASE2
• Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma — RECRUITING · PHASE1
• Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia — RECRUITING · PHASE2
• Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma — RECRUITING · PHASE2
• Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma — COMPLETED · PHASE1
• Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant — ACTIVE_NOT_RECRUITING · PHASE2
• Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma — COMPLETED · PHASE1
• Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL — ACTIVE_NOT_RECRUITING · PHASE2
• Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation — TERMINATED · PHASE2
• Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) — COMPLETED · PHASE2
• Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies — COMPLETED · PHASE1
• Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma — COMPLETED · PHASE1
• Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer — TERMINATED · PHASE1
• Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma — COMPLETED · PHASE2
• Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma — COMPLETED · PHASE2
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial — TERMINATED · PHASE1
• Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma — COMPLETED · PHASE1
• Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant — COMPLETED · PHASE2
• Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas — COMPLETED · PHASE1
• Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma — COMPLETED · PHASE2
• Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies — COMPLETED · PHASE1
• Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis — COMPLETED · PHASE2
• Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies — TERMINATED · PHASE2
• Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation — WITHDRAWN · PHASE2
• Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant — COMPLETED · PHASE1
• Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer — WITHDRAWN · PHASE2
• Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies — COMPLETED · PHASE1
• Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma — TERMINATED · PHASE1
• NK Cells in Cord Blood Transplantation — OTHER · PHASE1
• Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant — COMPLETED · PHASE1
• Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies — COMPLETED · PHASE2
• Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma — TERMINATED · PHASE1
• Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant — COMPLETED · PHASE2
• Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas — COMPLETED · PHASE1
• Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma — WITHDRAWN · PHASE1
• Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma — COMPLETED · PHASE2

Refine this search